These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19485424)

  • 1. Economic and human costs of restless legs syndrome.
    Reinhold T; Müller-Riemenschneider F; Willich SN; Brüggenjürgen B
    Pharmacoeconomics; 2009; 27(4):267-79. PubMed ID: 19485424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic burden of patients with restless legs syndrome in a German ambulatory setting.
    Dodel R; Happe S; Peglau I; Mayer G; Wasem J; Reese JP; Giani G; Geraedts M; Trenkwalder C; Oertel WH; Stiasny-Kolster K
    Pharmacoeconomics; 2010; 28(5):381-93. PubMed ID: 20297866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The real burden of restless legs syndrome: clinical and economic outcomes.
    Salas RE; Kwan AB
    Am J Manag Care; 2012 Oct; 18(9 Suppl):S207-12. PubMed ID: 23330575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Socioeconomic relevance of the idiopathic restless legs syndrome (RLS) in Germany: cost-of-illness study].
    Nelles S; Köberlein J; Grimm C; Pittrow D; Kirch W; Rychlik R
    Med Klin (Munich); 2009 May; 104(5):363-71. PubMed ID: 19444417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Humanistic and Economic Burden of Restless Legs Syndrome.
    Durgin T; Witt EA; Fishman J
    PLoS One; 2015; 10(10):e0140632. PubMed ID: 26501875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis.
    Padula WV; Phelps CE; Moran D; Earley C
    Sleep Med; 2017 Oct; 38():44-49. PubMed ID: 29031755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
    Meyers J; Candrilli S; Allen R; Manjunath R; Calloway M
    Manag Care; 2012 Oct; 21(10):44-51. PubMed ID: 23156076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and economic burden in patients with restless legs syndrome.
    Reese JP; Stiasny-Kolster K; Oertel WH; Dodel RC
    Expert Rev Pharmacoecon Outcomes Res; 2007 Oct; 7(5):503-21. PubMed ID: 20528395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids for restless legs syndrome.
    de Oliveira CO; Carvalho LB; Carlos K; Conti C; de Oliveira MM; Prado LB; Prado GF
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006941. PubMed ID: 27355187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary challenges and strategies for improving outcomes for patients with restless legs syndrome.
    Buchfuhrer MJ
    Am J Manag Care; 2012 Nov; 18(12 Suppl):S283-90. PubMed ID: 23327482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States.
    Allen RP; Bharmal M; Calloway M
    Mov Disord; 2011 Jan; 26(1):114-20. PubMed ID: 21322022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings.
    Trenkwalder C; Tinelli M; Sakkas GK; Dauvilliers Y; Ferri R; Rijsman R; Oertel W; Jaarsma J
    Eur J Neurol; 2021 Feb; 28(2):691-706. PubMed ID: 33043569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden.
    Lees M; Roberts G; Tabberer M; DasGupta R; Finnern HW;
    Curr Med Res Opin; 2008 Oct; 24(10):2919-30. PubMed ID: 18796188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregabalin for the Treatment of Restless Legs Syndrome.
    Griffin E; Brown JN
    Ann Pharmacother; 2016 Jul; 50(7):586-91. PubMed ID: 27091870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome.
    Talati R; Phung OJ; Mather J; Coleman CI
    Ann Pharmacother; 2009 May; 43(5):813-21. PubMed ID: 19401472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restless Legs Syndrome/Willis-Ekbom Disease Morbidity: Burden, Quality of Life, Cardiovascular Aspects, and Sleep.
    Stevens MS
    Sleep Med Clin; 2015 Sep; 10(3):369-73, xv-xvi. PubMed ID: 26329447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review.
    Giannaki CD; Hadjigeorgiou GM; Karatzaferi C; Pantzaris MC; Stefanidis I; Sakkas GK
    Kidney Int; 2014 Jun; 85(6):1275-82. PubMed ID: 24107848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for chronic kidney disease-associated restless legs syndrome.
    Gopaluni S; Sherif M; Ahmadouk NA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD010690. PubMed ID: 27819409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restless legs syndrome: a review of diagnosis and management in primary care.
    Bogan RK; Cheray JA
    Postgrad Med; 2013 May; 125(3):99-111. PubMed ID: 23748511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
    Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
    Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.